Biomedical subjects

Y Limony

Publications and source records attributed to Y Limony.

6 recordsLinked to original sources

PubMed2004

The childhood component of the ICP model is appropriate for growth analysis of short Israeli children.

OBJECTIVE: To determine whether the childhood component of the infancy-childhood-puberty (ICP) model is appropriate for growth analysis of short Israeli children. SUBJECTS AND METHODS: From 204 short, prepubertal children, 2-16 years of age, 1,516 height measurements were analyzed. For each child's measurements, a best-fitted line based on C equation of ICP has been drawn and the distribution of measurement points around that line was calculated. RESULTS: Ninety percent of the measurements were at a distance of no more than +/- 2 cm from the best-fitted ICP line. CONCLUSION: The C component of ICP model can be used as a growth analysis tool for shorter than average, prepubertal, Israeli children, older than 2 years of age.

Adolescent↗

PubMed1998

[Warning labels on medications--influence of warning labels and physicians' orders on patient behavior].

Compliance of 40 mothers with a warning label, "for external use," on a medicine package was checked in a survey in a primary care clinic for children. We also checked parents' attitudes to giving a medicine to their child when instructions given by the physician or by a friend contradicted the printed warning on the label. All mothers who were told that the medicine was recommended by their physicians accepted the recommendation without hesitation. Another group included 20 mothers who were told that the medicine was recommended by a friend. 9 of 20 mothers in this group refused to use the medicine. Talking with the nurse about the potential risk of medicine in general, some mothers, after second thought, refused to give the medicine to their child. At the end, 65% of recommendations made by a friend were rejected by mothers as compared to only 15% of the physicians' recommendations. 35 of 40 mothers (87%) understood the meaning of the warning label, but only 13 (32%) had noticed it at all. We conclude that patients may accept their physicians' recommendation to use a medicine despite a contradictory warning label much more readily than when it was recommended by a friend. Therefore, any intervention program intended to promote a more cautious use of medicines should include not only the explanations of the various warning labels but should also promote a change in the patient's behavior to a more active search for warning labels.

Adult↗

PubMed1998

Increase of serum lipoprotein (a) levels during growth hormone therapy in normal short children.

UNLABELLED: We studied the effect of growth hormone (GH) therapy on serum lipoprotein levels and the atherogenic index in short children without GH deficiency. Fasting blood samples were collected from ten (eight males) normal, short, prepubertal children, aged 6-12 years, before, during a 1-year course of GH therapy (0.1 IU/Kg/day), and 3 months after the cessation of GH administration. An increase in serum lipoprotein(a) [Lp(a)] levels of (mean% +/- SEM) 43 +/- 14, 58 +/- 18, 61 +/- 17 above the baseline levels was noted at 3 months (P < 0.05), 6 months (P < 0.01), and 1-year (P < 0.01) respectively after the beginning of GH administration. (ANOVA, P < 0.01). An inverse relationship between baseline serum Lp(a) concentrations and the percentage increment in Lp(a) after 9 months of GH therapy (r = -0.65, P < 0.05) was observed. GH therapy over a period of 1 year had no effect on plasma cholesterol, triglycerides, low density lipoprotein-cholesterol (LDL-C), high density lipoprotein cholesterol [HDL-C] concentrations and the atherogenic index. Three months after the cessation of GH therapy, serum Lp(a) levels were not significantly different from the pre-treatment values. CONCLUSIONS: Serum Lp(a) concentrations remained above pretreatment values during a 1-year period of GH treatment in short children without GH deficiency and declined shortly after cessation of therapy. Since GH therapy for short children without GH deficiency usually continues for several years, we suggest that serum Lp(a) levels should be determined and followed regularly in such children under prolonged GH therapy.

Analysis of Variance↗

PubMed1996

Final height prediction models for pubertal boys.

Accurate adult height prediction is of clinical importance in assessing the need for pharmacological intervention and in the evaluation of the outcome of therapy. The methods currently in use are subject to a wide range of error, one source of which is the use of bone age (BA) measurements. We have developed a computer model for predicting adult height in pubertal boys without using BA determinations. The model is based on the existing Infancy-Childhood-Puberty model and calculates the onset of the pubertal growth spurt. Predicted adult height was assessed using this new model and four others in a group of normal boys and in a group of short normal boys receiving growth hormone. Calculated final heights by all the methods were not significantly different. Incorporation of paternal height into the prediction equations increased the accuracy of the prediction. It was concluded that our new model is as accurate as existing methods of predicting final height that involve assessing BA.

Adolescent↗

PubMed1996

Short-term growth hormone therapy increases serum lipoprotein (a) levels in normal short children without growth hormone deficiency.

We investigated the short-term effect of GH (0.1 IU/kg/day) on serum lipoprotein (a) [Lp(a)] in 8 normal short children aged 6-12 years. GH increased serum Lp(a) concentrations in all the children studied. An increase to 107 +/- 5, 161.6 +/- 14.7 and 152.5 +/- 18.5% (mean +/- SE) of baseline levels was observed after 2 (p = NS), 6 (p < 0.01) and 12 weeks (p < 0.05), respectively. Our results suggest that GH therapy may pose a significant influence on Lp(a) serum levels in non-GH-deficient short children.

Body Height↗

PubMed1993

Improved method for predicting adult height of pubertal boys using a mathematical model.

Several methods for adult height prediction are currently in use. All are subject to a wide range of error which is thought to result, at least in part, from the use of bone age estimation. Following the suggestion made by Karlberg to predict adult height of pubertal children by the use of the 'Infancy-Childhood-Puberty model' (ICP), growth data of 39 normal boys who were followed from infancy until adult height was attained were reviewed. Use of the ICP model alone and without bone age resulted in more accurate predictions of adult height than those made by the methods which required bone age determination, the Bayley-Pinneu (BP) and the Tanner-Whitehouse methods (TW). The absolute error of prediction was 3.4 cm as compared to 5.3 (BP) and 4.9 cm (TW) (p < 0.05) and maximal range of error was 10 cm as compared to 22 (BP) and 21 cm (TW) (p < 0.05). Finally, based on the ICP model, a new equation which incorporates paternal height was been derived. This equation, termed ICP-New (ICPN), resulted in even better accuracy: absolute error of prediction was 2.3 cm as compared to 3.4 cm (ICP) and maximal range of error was 6 cm as compared to 10 cm (ICP) (p < 0.05). It is concluded that the ICP model and the ICPN equation may predict the adult height of pubertal boys more accurately than the methods which use bone age.

Adolescent↗